Gelonghui May 26 丨 Hengrui Pharmaceutical (600276)(600276freedoubledoublebonuspokergame.SH) announced that the company's subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd. received approval from the State Food and Drug Administration for the issuance of SHR-9839 for injection, SHR-A1921 for injection and SHR-A2009 for injectionfreedoubledoublebonuspokergameThe Drug Clinical Trial Approval Notice will be launched in the near future.
SHR-9839 for injection is a humanized antibody drug independently developed by the company. It is intended to be used to treat advanced malignant tumors. It plays an anti-tumor effect by simultaneously blocking two key signaling pathways related to tumor occurrence and development. SHR-A1921 for injection is an antibody-drug conjugate (ADC) that targets TROP2 tumor-associated antigen. After binding to the target antigen on the surface of tumor cells, it enters the cells through endocytosis, and kills tumor cells by releasing small molecule toxins. SHR-A2009 for injection is an antibody-drug conjugate targeting HER3. It can specifically bind to HER3 on the surface of tumor cells, and then be endocytosed into cells and transported into lysosomes, where it is hydrolyzed to release free toxins, killing tumor cells.
